Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Systemic lupus erythematosus (SLE) disease diagnosed ≥ 24 weeks before the screening visit
Meets the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE
One of the following: elevated antinuclear antibodies (ANA) ≥ 1:80 or positive anti- double-stranded deoxyribonucleic acid (dsDNA) (positive includes indeterminate results) or positive anti-Smith (anti-Sm) as determined by the central laboratory
Total Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≥ 6 points and clinical SLEDAI-2K score ≥ 4 points with joint involvement and/or rash \[score must be confirmed by Central Review Services (CRS)\]
Men and women must agree to follow specific methods of contraception, if applicable
You may not be if
Drug-induced SLE, certain other autoimmune diseases, and active, severe lupus nephritis
SLE overlap syndromes such as scleroderma and mixed connective tissue disease
Clinically significant abnormalities on chest x-ray or electrocardiogram (ECG)
History of any significant drug allergy
Clareo Health | An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
